Following the FDA approval of Truvada — the once-a-day pill that can drastically lower a person's risk of contracting HIV — Audie Cornish talks with Dr. Wafaa El-Sadr of Columbia University's Mailman School of Public Health. They examine the status of HIV prevention efforts in the U.S. today — what progress has been made and the challenges that still ahead. El-Sadr has worked on HIV/AIDS prevention and treatment since 1981.
New Drug Focuses Attention On HIV Prevention
News & Features National Public Radio · NPR ·